Lactulose Dosing Guidelines for Adult Patients

Chronic Idiopathic Constipation

Initial dose – Begin with 10–20 g (15–30 mL) of lactulose once daily; this is the FDA‑approved starting regimen for constipation. Evidence quality: very low to low certainty (based on two small RCTs in elderly nursing‑home residents). 1
Maximum dose – If the initial dose does not achieve the therapeutic goal, the dose may be increased up to 40 g (60 mL) per day. 1
Therapeutic target – Adjust the dose until the patient has 2–3 soft stools per day; this stool frequency defines adequate response. 1
Titration strategy – Start at the lower end of the dose range and increase gradually to minimise dose‑dependent bloating and flatulence. 1
Safety profile – Bloating and flatulence are very common and increase with higher doses; they can be mitigated by the gradual titration approach. Evidence quality: very low to low. 1
Cost – Generic lactulose is inexpensive and widely available, making it suitable for long‑term use; branded formulations are comparatively more costly. 1

Aggressive loading regimen – Administer 20–30 g (30–45 mL) of lactulose orally or via nasogastric tube every 1–2 hours until at least two bowel movements occur, to achieve rapid ammonia reduction. 2
Safety warning – Excessive dosing beyond the standard regimen does not improve clinical outcomes and may cause aspiration, dehydration, hypernatremia, severe perianal irritation, or paradoxical worsening of encephalopathy. 2

Standard maintenance dose – Give 20–30 g (30–45 mL) of lactulose orally three to four times daily. 2
Goal of therapy – Titrate to maintain 2–3 soft stools per day, which is the accepted clinical marker of therapeutic efficacy. [3][2]
Indefinite continuation – Continue the maintenance regimen indefinitely after resolution of an overt episode; discontinuation is associated with a high risk of recurrence. Weak recommendation (77 % expert consensus). 4

Retention enema preparation – Mix 300 mL of lactulose with 700 mL of water (total 1 L). Administer via rectal balloon catheter, retain for 30–60 minutes, and repeat every 4–6 hours as needed. Transition to oral dosing as soon as the patient can safely swallow. 2

First‑line agent – Lactulose is the recommended first‑line therapy for secondary prophylaxis immediately after a first overt hepatic encephalopathy episode. [3][4]
Recurrence reduction – In an open‑label RCT, lactulose lowered the 14‑month recurrence risk to 20 % versus 47 % in patients not receiving lactulose. High‑quality evidence (RCT). 3

Add‑on therapy – Add rifaximin 550 mg twice daily to ongoing lactulose after a second overt episode within six months. [3][4]
Combination benefit – Lactulose + rifaximin yields a 76 % recovery rate within 10 days versus 44 % with lactulose alone and reduces hospitalisations. Evidence from comparative studies. [2][4]
Concurrent use – In the pivotal rifaximin trial, 91 % of participants were already on lactulose, supporting combined therapy rather than rifaximin monotherapy. 3

Hypernatremia risk – Producing more than 2–3 soft stools per day markedly increases the risk of hypernatremia through volume depletion; monitor serum sodium regularly during aggressive lactulose therapy. 2
AGA guideline recommendation (2025) – Modify or discontinue lactulose (and diuretics) when treating hypervolemic hyponatraemia (serum Na < 130 mEq/L) in cirrhotic patients with ascites. Strong recommendation from the American Gastroenterological Association. 2

Polyethylene glycol (PEG) – PEG can replace lactulose for acute hepatic encephalopathy when lactulose is unavailable or contraindicated (e.g., ileus, marked abdominal distention). A typical regimen is 4 L administered orally over 4 hours; some data suggest faster encephalopathy resolution, but further validation is required. 2